Abstract: The present application relates to the field of pharmaceutical chemistry, and specifically to cyclopropanecarboxamide-containing compounds of formula (I) and application thereof. The cyclopropanecarboxamide-containing compounds have great medical value and market potential for autoimmune diseases and myeloproliferative neoplasm diseases.

Abstract: The present application provides compounds as shown in Formula (I) and uses thereof. The compounds shown in Formula (I) provided by the present application may serve as effective glucagon-like peptide-1 (GLP-1) receptor agonists. They have excellent GLP-1R receptor agonist activity and significant blood glucose-reducing effect, have better pharmacokinetic characteristics, represent more options for the prevention and/or treatment of GLP-1 activity-related diseases, conditions, or disorders, and thereby have better clinical application prospects.

Abstract: The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to compounds with ALK inhibitory activity and preparation method and use thereof. The compounds with ALK inhibitory activity provided by the present application are ALK inhibitors for treating diseases responsive to the inhibition of ALK kinase, can be used for treating ALK-positive diseases, such as tumors and cancers, and have broad application prospects.

Abstract: Provided is a pyrimidine derivative, a preparation method and a use thereof, wherein the pyrimidine derivative is selected from a compound represented by Formula (I), or a tautomer, an enantiomer, a diastereomer, a mesomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt or prodrug thereof. The pyrimidine derivative shows an excellent CDK-inhibiting effect and action.

Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.

Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.